Long‐term survival of dogs with stage 4 oral malignant melanoma treated with anti‐canine PD‐1 therapeutic antibody: A follow‐up case report.

MLA

Igase, Masaya, et al. “Long‐term Survival of Dogs with Stage 4 Oral Malignant Melanoma Treated with Anti‐canine PD‐1 Therapeutic Antibody: A Follow‐up Case Report.” Veterinary & Comparative Oncology, vol. 20, no. 4, Dec. 2022, pp. 901–05. EBSCOhost, https://doi.org/10.1111/vco.12829.

APA

Igase, M., Inanaga, S., Tani, K., Nakaichi, M., Sakai, Y., Sakurai, M., Kato, M., Tsukui, T., & Mizuno, T. (2022). Long‐term survival of dogs with stage 4 oral malignant melanoma treated with anti‐canine PD‐1 therapeutic antibody: A follow‐up case report. Veterinary & Comparative Oncology, 20(4), 901–905. https://doi.org/10.1111/vco.12829

Chicago

Igase, Masaya, Sakuya Inanaga, Kenji Tani, Munekazu Nakaichi, Yusuke Sakai, Masashi Sakurai, Masahiro Kato, Toshihiro Tsukui, and Takuya Mizuno. 2022. “Long‐term Survival of Dogs with Stage 4 Oral Malignant Melanoma Treated with Anti‐canine PD‐1 Therapeutic Antibody: A Follow‐up Case Report.” Veterinary & Comparative Oncology 20 (4): 901–5. doi:10.1111/vco.12829.